Bayer registers Phase 1 sevabertinib-metformin interaction study in healthy adults
A new Bayer-sponsored trial testing sevabertinib's effect on metformin pharmacokinetics was registered, alongside a Tuebingen cardiac amyloidosis study Bayer is collaborating on.
Two Bayer-linked items were registered or updated this week.
- NCT07753252 is a Phase 1, open-label, fixed-sequence crossover study examining whether sevabertinib changes how the body handles metformin in healthy adults1. The study is grounded in the hypothesis that sevabertinib may block kidney transporters called MATE1 and MATE2-K, which help remove metformin from the body1. The record lists the study as recruiting, with an actual start date of 2026-08-25 and an estimated primary completion date of 2026-10-221, enrolling 40 participants1 with Bayer as the sponsor.
- NCT07752732 ("NIS-TAVI-AMY"), sponsored by University Hospital Tuebingen with Bayer as a collaborator, is a prospective observational study evaluating multimodal imaging biomarkers for the detection and characterization of cardiac amyloidosis in patients with severe AS undergoing TAVI evaluation2. The study is listed as recruiting, with an actual start date of 2020-01-142 and an estimated primary completion date of 2027-12-31.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.